Skip to content

Cubist Pharmaceuticals a long-term buy?

FBN’s Charles Payne, NewOak Capital President James Frischling, small business expert Susan Solovic, retail analyst Hitha Prabhakar and Penn Financial Group founder Matt McCall on the outlook for Cubist Pharmaceuticals.

Add Your Comment (Get a Gravatar)

Get a Gravatar! Your Name

Your email address will not be published. Required fields are marked *.

*

Time limit is exhausted. Please reload CAPTCHA.